Walter Siegel - Henry Schein VP Officer
HS2 Stock | EUR 68.58 0.04 0.06% |
Insider
Walter Siegel is VP Officer of Henry Schein
Age | 63 |
Phone | 631 843 5500 |
Web | https://www.henryschein.com |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0642 % which means that it generated a profit of $0.0642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1211 %, meaning that it generated $0.1211 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities.Henry Schein has accumulated 1.04 B in total debt with debt to equity ratio (D/E) of 41.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Henry Schein has a current ratio of 1.62, which is within standard range for the sector. Debt can assist Henry Schein until it has trouble settling it off, either with new capital or with free cash flow. So, Henry Schein's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Henry Schein sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Henry to invest in growth at high rates of return. When we think about Henry Schein's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
Yaohua Zhang | Shanghai Pharmaceuticals Holdin | 45 | |
Dave Lardy | Patterson Companies | N/A | |
Jianyi Mao | Shanghai Pharmaceuticals Holdin | 50 | |
Kevin Pohlman | Patterson Companies | 59 | |
Wenxun Huo | Shanghai Pharmaceuticals Holdin | 62 | |
Michelle Greene | Cardinal Health | N/A | |
Jason Hollar | Cardinal Health | 50 | |
Chaoyang Gu | Shanghai Pharmaceuticals Holdin | 53 | |
Liang Hong | Shanghai Pharmaceuticals Holdin | 43 | |
Dawei Liu | Shanghai Pharmaceuticals Holdin | 38 | |
Shui ACS | Shanghai Pharmaceuticals Holdin | 46 | |
Stephen Mason | Cardinal Health | 51 | |
Man Cho | Shanghai Pharmaceuticals Holdin | 62 | |
Kevin Barry | Patterson Companies | 45 | |
Yong Zhao | Shanghai Pharmaceuticals Holdin | 47 | |
Jiangnan Cai | Shanghai Pharmaceuticals Holdin | 61 | |
Craig Cowman | Cardinal Health | N/A | |
Haoliang Gu | Shanghai Pharmaceuticals Holdin | 57 | |
Ying Ke | Shanghai Pharmaceuticals Holdin | N/A | |
Tim Rogan | Patterson Companies | 52 | |
Jinqi Yu | Shanghai Pharmaceuticals Holdin | N/A |
Management Performance
Return On Equity | 0.12 | |||
Return On Asset | 0.0642 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Ettinger, Ex COO | ||
Walter Siegel, VP Officer | ||
Graham Stanley, VP Officer | ||
Stanley Bergman, Ex CEO | ||
Steven Paladino, Ex Director | ||
Ronald South, VP CFO | ||
Mark Mlotek, Chief VP | ||
Olga Timoshkina, Chief Fin | ||
Christopher Pendergast, VP CTO | ||
James Breslawski, Ex Pres |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.12 | |||
Return On Asset | 0.0642 | |||
Profit Margin | 0.04 % | |||
Operating Margin | 0.07 % | |||
Current Valuation | 11.9 B | |||
Shares Outstanding | 131.28 M | |||
Shares Owned By Insiders | 1.01 % | |||
Shares Owned By Institutions | 98.99 % | |||
Price To Earning | 16.81 X | |||
Price To Book | 3.09 X |
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Additional Information and Resources on Investing in Henry Stock
When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Henry Stock please use our How to Invest in Henry Schein guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.